Source link : https://www.newshealth.biz/health-news/survival-benefit-with-adjuvant-t-dm1-in-high-risk-her2-positive-breast-cancer/
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial. Estimated overall survival (OS) at 7 years was 89.1% with adjuvant T-DM1 versus 84.4% with adjuvant trastuzumab (Herceptin). Consistent with earlier reports from the study, the 7-year invasive disease-free survival (iDFS) […]
Author : News Health
Publish date : 2025-01-16 20:57:04
Copyright for syndicated content belongs to the linked Source.